Ask AI
Global RR CLL Italy

CE / CME

Italy—Regional Perspectives on the Management of Patients With R/R CLL/SLL

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: April 14, 2026

Expiration: October 13, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 64-year-old man with Rai stage IV CLL (diagnosed 2016; unmutated IGHV, del11q, TP53 wild-type) and a history of hypertension was initially treated with ibrutinib plus rituximab (2016-2020) until progression, followed by venetoclax plus rituximab with good response and subsequent venetoclax maintenance. In March 2026, he developed symptomatic relapse with lymphadenopathy and cytopenias and was found to have a BTK C481S resistance mutation with TP53 still negative.

Which of the following is a guideline supported treatment option for this patient with R/R CLL?

2.

In the phase I CaDAnCe-101 study evaluating the BTK degrader BGB-16673 in heavily pretreated patients with R/R CLL/SLL, which of the following patient populations showed response rates >70%?

3.

A 66-year-old man with CLL (trisomy 12, unmutated IGHV, TP53 intact) relapsed approximately 8 months after first-line ibrutinib and is now considering treatment with venetoclax plus rituximab. Current evaluation shows an absolute lymphocyte count of 24K, hemoglobin ~10 g/dL, platelets 90K, lymphadenopathy up to 4.5 cm, and splenomegaly to 15 cm, with otherwise normal labs.

Can this patient start venetoclax in the outpatient setting?